Post-Market Drug Surveillance

Post-market drug surveillance is the safety counterweight to faster approval in Supercharging a New FDA: Marty Makary on Science, Power & Patients. Marty Makary argues that approval should not be the end of FDA attention and says the FDA should keep “eyes on a drug” after it reaches patients.

The source uses Vioxx and opioids as examples where national patterns or safety signals were recognized too late. Makary’s answer is a big-data monitoring posture that can find subgroup risks, drug-drug interactions, and safety signals that premarket trials may be too small or too short to expose.

Key Claims

• Faster approvals are safer if post-market monitoring is stronger and continuous.
• Safety signals can emerge from real-world use, especially in subgroups or drug combinations not well represented in trials.
• Surveillance is not a substitute for premarket evidence; it is a second layer that changes the approval-risk tradeoff.
• The concept depends on data quality, privacy, causal inference, and clear authority to act when signals appear.

Connections

• FDA Review Modernization and Clinical Trial Continuity - faster and more continuous review context.
• FDA and Marty Makary - agency and source speaker.
• Clinical Development Capability - premarket evidence side of the same drug-lifecycle problem.
• Medical Risk Management - broader healthcare safety frame.